Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Expert Rev Proteomics ; 18(8): 707-717, 2021 08.
Article in English | MEDLINE | ID: covidwho-1380972

ABSTRACT

INTRODUCTION: Active matrix metalloproteinase (aMMP)-8 utilized in point-of-care testing (POCT) is regarded as a potential biomarker for periodontal and peri-implant diseases. Various host and microbial factors eventually influence the expression, degranulation, levels and activation of aMMP-8. The type of oral fluids (saliva, mouthrinse, gingival crevicular, and peri-implant sulcular fluids [GCF/PISF], respectively) affect the analysis. AREAS COVERED: With this background, we aimed to review here the recent studies on practical, inexpensive, noninvasive and quantitative mouthrinse and GCF/PISF chair-side POCT lateral flow aMMP-8 immunoassays (PerioSafe and ImplantSafe/ORALyzer) and how they help to detect, predict, monitor the course, treatment and prevention of periodontitis and peri-implantitis. The correlations of aMMP-8 POCT to other independent and catalytic activity assays of MMP-8 are also addressed. EXPERT OPINION: The mouthrinse aMMP-8 POCT can also detect prediabetes/diabetes and tissue destructive oral side-effects due to the head and neck cancers' radiotherapy. Chlorhexidine and doxycycline can inhibit collagenolytic human neutrophil and GCF aMMP-8. Furthermore, by a set of case-series we demonstrate the potential of mouthrinse aMMP-8 POCT to real-time/online detect periodontitis as a potential risk disease for coronavirus disease 2019 (COVID-19). The clinical interdisciplinary utilization of aMMP-8 POCT requires additional oral, medical, and interdisciplinary studies.


Subject(s)
COVID-19/enzymology , Matrix Metalloproteinase 8/metabolism , Pandemics , SARS-CoV-2 , Biomarkers/analysis , Biomarkers/metabolism , COVID-19/complications , COVID-19/drug therapy , Diabetes Mellitus/diagnosis , Diabetes Mellitus/enzymology , Doxycycline/therapeutic use , Humans , Immunoassay/methods , Matrix Metalloproteinase 8/analysis , Mouthwashes , Oral Hygiene , Peri-Implantitis/diagnosis , Peri-Implantitis/enzymology , Periodontitis/complications , Periodontitis/diagnosis , Periodontitis/enzymology , Point-of-Care Testing , Radiotherapy/adverse effects , Risk Factors
3.
Br J Radiol ; 94(1117): 20200466, 2021 Jan 01.
Article in English | MEDLINE | ID: covidwho-895048

ABSTRACT

Covid-19 is a morbid respiratory disease that has caused desperate times on a global scale due to the lack of any effective medical treatment. Some in the radiation community are actively proposing low-dose radiation therapy (LDRT) for managing the viral pneumonia associated with Covid-19. This commentary provides a rationale for exercising caution against such a decision as the efficacy of LDRT for viral diseases is unknown, while its long-term adverse risks are well known.


Subject(s)
COVID-19/radiotherapy , Humans , Radiotherapy/adverse effects , Radiotherapy Dosage
4.
CA Cancer J Clin ; 70(6): 480-504, 2020 11.
Article in English | MEDLINE | ID: covidwho-750753

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID-19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio-oncology and outlines key modifications in the approach to this ever-increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS-CoV-2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.


Subject(s)
Antineoplastic Agents/adverse effects , COVID-19/complications , Cardiovascular Diseases/etiology , Cross Infection/prevention & control , Neoplasms/complications , Neoplasms/therapy , Anthracyclines/adverse effects , COVID-19/physiopathology , COVID-19/prevention & control , COVID-19/transmission , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/therapy , Humans , Proteasome Inhibitors/adverse effects , Protein Kinase Inhibitors/adverse effects , Radiotherapy/adverse effects , Receptor, ErbB-2/antagonists & inhibitors , Referral and Consultation , SARS-CoV-2 , Trastuzumab/adverse effects
6.
Endocrine ; 70(1): 1-5, 2020 10.
Article in English | MEDLINE | ID: covidwho-697114

ABSTRACT

The recent coronavirus infectious disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is placing health systems in serious challenges worldwide. Shocking statistics each day has prompted the World Health Organization to officially declare the COVID-19 outbreak as a pandemic in March 2020. Preliminary studies have shown increased mortality in patients with solid cancers and infection by SARS-CoV-2. Until now, the evidence on the behavior of COVID-19 in patients with a history of thyroid cancer remains scarce, and most of the recommendations given are based on common sense. Therefore, in this viewpoint, we present a brief review of several challenges we are frequently facing during this pandemic and a series of recommendations based on what we have implemented in our clinical practice at a university hospital currently mostly dedicated to COVID-19.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Thyroid Neoplasms/epidemiology , Biopsy, Fine-Needle/adverse effects , COVID-19 , Comorbidity , Coronavirus Infections/immunology , Humans , Immune System , Iodine Radioisotopes/adverse effects , Iodine Radioisotopes/therapeutic use , Pandemics , Pneumonia, Viral/immunology , Protein Kinase Inhibitors/adverse effects , Radiotherapy/adverse effects , Risk Factors , SARS-CoV-2 , Thyroid Neoplasms/immunology , Thyroid Neoplasms/therapy , Thyroxine/therapeutic use , World Health Organization
SELECTION OF CITATIONS
SEARCH DETAIL